HIGHLIGHTS
- who: Joost G. E. Verbeek from the patients with stage III, HER2-negative, HRD breast cancer in the Netherlands have published the research: High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation, in the Journal: (JOURNAL)
- what: To increase the chance of successful introduction of HDCT into daily clinical practice the authors aimed to identify relevant factors for smooth implementation using an early comprehensive assessment framework. This trial investigates multiple outcomes, such as prognosis, quality of life, effect of chemotherapy on cognition, and cost-effectiveness . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.